GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists
PISCATAWAY, N.J., April 23, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been selected as finalists for the Entrepreneur Of The Year® 2026 New Jersey Award by Ernst & Young LLP. GenScript CEO Sherry Shao The Entrepreneur Of The...
Budget Maid Agency Marks 25 Years with Enhanced Training and Digital Solutions for Domestic Helper Placement in Singapore
SINGAPORE, April 22, 2026 /PRNewswire/ -- Budget Employment Service Centre Pte Ltd ("Budget Maid Agency") is marking its 25th anniversary in 2026, celebrating a longstanding commitment to supporting families in Singapore with reliable domestic helper placement services. Founded in 2001, the agency has assisted households across Singapore in securing suitable domestic helpers for housekeeping, childcare, and eldercare. As demand...
Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are considered "druggable," and notably, all approved drugs to date act on only 716 distinct targets. The challenge in identifying a therapeutic target gene that...
Manulife and the World Economic Forum’s UpLink Initiative Launch Canadian Longevity Innovation Challenge
'Shaping Canada's Longevity Advantage' challenge will invite innovators to deliver solutions that strengthen health, financial resilience and social connection across longer lives The challenge is an initiative of Manulife's Longevity Institute, driving Canadian solutions for a longer‑living society TORONTO, April 22, 2026 /PRNewswire/ -- Manulife, in partnership with UpLink, the World Economic Forum's early-stage innovation initiative, and the Forum's...
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75%...
Samsung Biologics Reports First Quarter 2026 Financial Results
Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion Performance driven by full utilization across Plants 1 through 4 and robust operational execution Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEON, South Korea, April 22, 2026 /PRNewswire/ -- Samsung Biologics...
NEW TELE-DENTISTRY PROGRAMME SUPPORTS EARLY INTERVENTION FOR CHILDREN AT RISK OF CARIES
Targeting vulnerable families, the collaborative programme empowers parents with personalised insights and clear, prioritised guidance for their children's oral care SINGAPORE, April 22, 2026 /PRNewswire/ -- For many families, dental care decisions tend to be reactive, made only when a child experiences pain or visible dental problems, by which time treatment can be...
ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform ‘LMT15’
ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology Technology excellence validated by winning first place at 'Novo Nordisk Partnering Day Korea 2026' SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and...
AscendCare Medical Clinic Launches Public Awareness Initiative to Normalise Regular Health Screening in Singapore
SINGAPORE, April 22, 2026 /PRNewswire/ -- AscendCare Medical Clinic, a modern healthcare provider based in Tanjong Pagar, today announced a new public education initiative designed to reframe health screenings as a routine and responsible component of personal wellness. The campaign addresses a critical public health gap in Singapore: the persistence of stigma and misinformation that frequently leads to delayed...
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with albumin-bound...
